{
  "abstract": "Background: Survival differences by age are well recognized in adult acute lymphoblastic leukemia/lymphoma (ALL/LBL), but their timing, competing-mortality structure, and behavior across recent diagnosis periods remain less clear.\n\nMethods: This retrospective SEER cohort included adults diagnosed during 2010-2023, excluding Burkitt leukemia/lymphoma. We estimated overall survival (OS), 3-year restricted mean survival time (RMST), and cumulative incidence of ALL/LBL-attributable and other/unknown-cause death. Cox, Fine-Gray, spline, and exploratory time-split models assessed age associations.\n\nResults: Among 9,491 patients, 4,618 died: 3,828 deaths were attributed to ALL/LBL and 790 to other or unknown causes. Three-year RMST was 1.89, 2.10, and 2.14 years in 2010-2014, 2015-2019, and 2020-2023, respectively; the recent-period difference was 0.044 years (95% CI -0.016 to 0.104; P = 0.150). Median follow-up in 2020–2023 was 22 months. Compared with age 18–39 years, the adjusted overall-mortality HR for age >=75 years was 6.258 (95% CI 5.627-6.960). Because proportional hazards were violated, this HR should be read as a summary association. The exploratory HR was 8.201 (95% CI 7.224-9.311) during the first year and 3.496 (95% CI 2.885-4.236) thereafter. At 3 years, cumulative incidence in patients aged >=75 years was 70.4% for ALL/LBL-attributable death by registry attribution and 12.8% for other/unknown-cause death. The spline test supported departure from linearity (P<0.001); the age-by-period interaction was not significant (P = 0.182), whereas an exploratory age-by-subtype interaction was nominally significant (P = 0.024, unadjusted for multiplicity).\n\nConclusion: Older age was associated with higher mortality, especially in the first year after diagnosis. ALL/LBL-attributable death predominated by registry attribution even in the oldest group. The 3-year comparison did not establish a survival difference between 2015–2019 and 2020-2023; limited follow-up and residual case-mix differences preclude concluding that progress has stopped.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China",
    "The First Clinical Medical College, Zunyi Medical University, Zunyi, Guizhou, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zhe Li"
    },
    {
      "affs": [
        1
      ],
      "name": "Jianglin Yu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fsb4rpnr88a6j.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1913564",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13696205/",
  "id": "fsb4rpnr88a6j",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://doi.org/10.3389/fonc.2026.1913564",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2739|Acute Lymphoblastic Leukemia research"
    ]
  ],
  "openalex": "W7221480409",
  "pdf_url": "https://europepmc.org/articles/PMC13696205?pdf=render",
  "pmcid": "PMC13696205",
  "pmid": "42935729",
  "published": "2026-10-12",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/fsb4rpnr88a6j.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:36Z",
      "native_id": "PMC13696205",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1913564"
    },
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1913564",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1913564/full"
    },
    {
      "first_seen": "2026-10-30T12:22:24Z",
      "native_id": "MED:42935729",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42935729"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2739|Acute Lymphoblastic Leukemia research",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Age-stratified survival and competing mortality in adult acute lymphoblastic leukemia and lymphoblastic lymphoma: a population-based competing-risk and restricted mean survival analysis",
  "title_text": "Age-stratified survival and competing mortality in adult acute lymphoblastic leukemia and lymphoblastic lymphoma: a population-based competing-risk and restricted mean survival analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:33:35Z",
  "url": "https://research.draconitic.com/paper/fsb4rpnr88a6j",
  "venue": "Frontiers in Oncology",
  "versions": []
}